share_log

Awakn Life Sciences Announces Credit Facility

Awakn Life Sciences Announces Credit Facility

Awakn生命科學公司宣佈信貸融資
newsfile ·  2024/12/18 21:30

Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has obtained an unsecured credit facility of up to US$535,000 (the "Facility") from an arm's length creditor of the Company, which can be drawn upon by the Company in multiple advances, and which is evidenced by a grid promissory note issued by the Company (the "Grid Note"). The principal drawn under the Facility shall become due and payable on December 5, 2026 (the "Maturity Date"), and bears interest at 10% per annum also payable on the Maturity Date.

安大略省多倫多--(Newsfile CORP.,2024年12月18日)——開發藥物濫用和心理健康障礙療法的臨牀階段生物技術公司Awakn Life Sciences CORP.(CSE:AWKN)(OTCQB:AWKNF)(FSE:954)(「Awakn」 或 「公司」)欣然宣佈,它已獲得高達53.5萬美元的無抵押信貸額度(「該設施」)”)來自公司的獨立債權人,公司可以通過多次預付款提取該債權人,公司發行的網格本票(「網格票據」)證明了這一點。根據該融資機制提取的本金應於2026年12月5日(「到期日」)到期並支付,年利率爲10%,也應在到期日支付。

The Grid Note contains certain other customary financial and other covenants and any principal drawn will be used for general working capital purposes. The Facility is intended to provide the Company with immediate capital while it continues to advance its research and development projects, and seek out other potential sources of capital.

網格票據包含某些其他慣常財務和其他契約,任何提取的本金將用於一般營運資金用途。該融資機制旨在爲公司提供即時資本,同時繼續推進其研發項目,並尋找其他潛在的資本來源。

"We continue to make significant progress on research programs, including our lead program AWKN-001 which is in phase 3 in the UK and AWKN-002 which in in phase 2 planning in the US and this Facility extends our runway as we progress towards new milestones," stated Anthony Tennyson, Awakn CEO.

Awakn首席執行官安東尼·坦尼森表示:「我們在研究項目上繼續取得重大進展,包括我們在英國的牽頭項目 AWKN-001 和在美國處於第二階段規劃的 AWKN-002,隨着我們邁向新的里程碑,該設施延長了我們的跑道。」

About Awakn Life Sciences Corp.
Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing therapeutics targeting addiction. Awakn has a near-term focus on Alcohol Use Disorder, a condition affecting approximately 29 million adults in the US and approximately 40 million in the US and key European markets for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercializing our R&D pipeline across multiple channels.

Awakn 生命科學公司簡介
Awakn Life Sciences CORP. 是一家處於臨牀階段的生物技術公司,開發針對成癮的療法。Awakn的近期重點是酒精使用障礙,這種疾病影響了美國約2900萬成年人,在美國和主要歐洲市場影響了約4000萬名成年人,目前的護理標準不足以應對這種情況。我們的目標是爲急需的成癮患者提供突破性療法,我們的戰略側重於通過多個渠道將我們的研發渠道商業化。

| Twitter | LinkedIn

| 推特 | 領英

Notice Regarding Forward-Looking Information

關於前瞻性信息的通知

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-Looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

本新聞稿包含適用的證券法(以下統稱爲 「前瞻性陳述」)中定義的某些前瞻性信息和前瞻性陳述。前瞻性陳述反映了當前對未來事件或公司未來業績的預期或信念。除歷史事實陳述以外的所有陳述均爲前瞻性陳述。通常,但並非總是如此,前瞻性陳述可以通過使用 「計劃」、「期望」、「預期」、「預算」、「預期」、「估計」、「繼續」、「預測」、「項目」、「預測」、「打算」、「預期」、「目標」 或 「相信」 等詞語來識別,或者這些詞語和短語或陳述的否定詞,「可能」、「可能」、「將」、「應該」、「可能」 或 「將」 被採取、發生或實現的事件或結果,包括與公司業務有關的聲明。所有前瞻性陳述,包括本文中的前瞻性陳述,均受本警示性陳述的限制。

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include, but are not limited to: fluctuations in general macroeconomic conditions; the business plans and strategies of the Company; the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; fluctuations in securities markets; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; expectations regarding the size of the addiction market; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

儘管公司認爲此類陳述中表達的預期基於合理的假設,但此類陳述並不能保證未來的業績,實際業績或發展可能與聲明中的業績或發展存在重大差異。某些因素可能導致實際業績與前瞻性信息中的結果存在重大差異。其中包括但不限於:總體宏觀經濟狀況的波動;公司的業務計劃和戰略;公司在高度監管的企業中遵守所有適用的政府法規的能力;投資運營歷史有限或沒有運營歷史且從事某些司法管轄區目前被視爲非法活動的目標公司或項目的固有風險;法律變化;運營歷史有限;對管理的依賴;對額外融資的要求;競爭;證券市場的波動;公衆對迷幻藥物醫療用途的看法和看法不一致;對成癮市場規模的預期;以及監管或政治變革。提醒讀者,上述因素清單並未詳盡列出可能影響前瞻性陳述的因素。因此,讀者不應過分依賴前瞻性陳述。本新聞稿中的前瞻性陳述僅代表截至本新聞稿發佈之日或此類陳述中規定的一個或多個日期。

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at . The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

投資者請注意,任何此類陳述都不能保證未來的表現,實際業績或發展可能與前瞻性信息中的預測存在重大差異。有關該公司的更多信息,鼓勵投資者在SEDAR上查看公司的公開文件,網址爲。除法律要求外,公司不打算或義務更新或修改任何前瞻性信息,無論是由於新信息、未來事件還是其他原因。

Investor Enquiries:
Anthony Tennyson, CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
416-270-9566

投資者查詢:
安東尼·坦尼森,Awakn Life Sciences首席執行官
anthony.tennyson@awaknlifesciences.com
416-270-9566

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論